Halozyme Therapeutics, Inc. (HALO) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Diego, CA, 미국. 현재 CEO는 Helen I. Torley.
HALO 을(를) 보유 IPO 날짜 2004-03-16, 350 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $7.97B.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company headquartered in San Diego, California, with operations across the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. The company's core proprietary technology, ENHANZE, is based on a recombinant human hyaluronidase enzyme (rHuPH20) that enables subcutaneous delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Halozyme develops and commercializes multiple products across oncology, immunology, and rare disease areas, including Hylenex, RITUXAN HYCELA, HYQVIA, and collaborates with leading pharmaceutical companies such as Roche, Pfizer, AbbVie, and Bristol-Myers Squibb on various therapeutic programs targeting cancer, autoimmune diseases, and infectious diseases. Founded in 1998, the company leverages its advanced drug delivery platform to enhance the efficacy and patient convenience of treatments across multiple therapeutic areas.
